

# **Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021**

**ENGLEWOOD, CO / May 10, 2021** / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at 4:30 p.m. ET to report its financial results for the fiscal third quarter ended March 31, 2021 and review recent accomplishments.

## **Conference Call Information**

877-407-9124 (toll-free)

201-689-8584 (international)

The webcast will be accessible live and archived at the following link <https://www.webcaster4.com/Webcast/Page/2142/40724> and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at **aytubio.com**, for 90 days.

A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 40724.

## **About Aytu BioPharma, Inc.**

Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING). The company's other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company's evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. Aytu is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome (vEDS), a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. There are no currently approved treatments for vEDS.

To learn more, please visit [aytubio.com](http://aytubio.com).

**Contact for Media and Investors:**

Sarah McCabe  
Stern Investor Relations, Inc.  
[sarah.mccabe@sternir.com](mailto:sarah.mccabe@sternir.com)

**SOURCE:** Aytu BioPharma, Inc.

View source version on [accesswire.com](http://accesswire.com):

<https://www.accesswire.com/646144/Aytu-BioPharma-to-Report-Third-Quarter-Fiscal-2021-Results-on-May-17-2021>

